Showing 329 results
September 2023
-
Media ReleaseSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in EuropeBiosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from…
-
Media ReleaseNovartis confirms Sandoz Spin-off for October 4, 2023Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
-
Media ReleaseSandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumabPositive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
-
Media ReleaseNovartis shareholders approve the proposed 100% Spin-off of SandozShareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-…
-
Media ReleaseSandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offeringAgreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to…
-
Media ReleaseSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statementsAd hoc announcement pursuant to Art. 53 LR Supplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023 H1 results demonstrated continued momentum with…
August 2023
-
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolioSandoz completes acquisition of worldwide brand rights for Mycamine®(micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly reinforce…
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosisBiosimilar Tyruko®approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients in US,…
-
Media ReleaseSandoz AG expands reach of Hyrimoz® (adalimumab-adaz) in US through commercialization agreement with CordavisSandoz AG and Cordavis announce agreement to commercialize Hyrimoz® (adalimumab-adaz) in US under Cordavis private label Cordavis will release and commercialize private-labeled Hyrimoz in US…
-
Media ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off voteAd hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issued Sandoz Listing Prospectus…
-
Media ReleaseSandoz announces positive results from Mylight Phase lll study for biosimilar afliberceptMylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference aflibercept Results offer hope of new affordable option for patients with nAMD, a…